An ethno-epidemiological study to advance HIV prevention and treatment for PWUD

项目总结/摘要 在COVID-19疫情造成的中断中，包括服务中断和公共卫生 强调呆在家里的命令，感染艾滋病毒的PWUD可能会增加感染艾滋病毒的风险 治疗途径和依从性结果。我们要求行政补充检查 COVID-19相关中断对感染艾滋病毒的PWUD的影响，重点是治疗的获得和 遵守，以及组织层面对COVID相关风险管理的应对措施。我们建议 我在加拿大的温哥华进行这项工作，这是一个理想的环境，因为它是拟议的研究 特点是：1）大量的艾滋病毒感染者; 2）全面和创新的艾滋病毒 预防和治疗干预措施，也在其他环境中实施;以及3）正在进行 国家药物滥用研究所（NIDA）资助的PWUD队列研究，有助于我们的民族， 流行病学研究和联合收割机结合临床和定性数据的能力。 在我们研究艾滋病毒预防和治疗的基础设施和经验的基础上， 我们建议研究以下目标： · AIM 1。研究COVID-19大流行的影响，包括公共卫生措施，如 关于共同管理艾滋病毒和其他健康状况的居家令和身体距离 艾滋病毒感染者和复杂的合并症中。 · AIM 2。确定COVID-19期间艾滋病毒治疗的系统层面障碍和促进因素 大流行病，包括抗逆转录病毒疗法的发放，特别是在需要艾滋病毒治疗援助的人群中 复杂的合并症，并确定在COVID-19期间进行的组织适应 艾滋病毒服务机构提供全面的护理模式。 6

PROJECT SUMMARY/ABSTRACT Amidst disruptions stemming from the COVID-19 pandemic, including service interruptions and public health emphasis on stay-at-home orders, PWUD living with HIV may experience increased risk of suboptimal HIV treatment access and adherence outcomes. We are requesting an administrative supplement to examine the impact of COVID-19-related disruptions on PWUD living with HIV, focusing on treatment access and adherence, and organizational-level responses to the management of COVID-related risk. We propose to undertake this work in Vancouver, Canada, which is an ideal setting for the proposed research as it is characterized by: 1) a large population of PWUD living with HIV; 2) comprehensive and innovative HIV prevention and treatment interventions, which have also been implemented in other settings; and 3) ongoing National Institute on Drug Abuse (NIDA)-funded cohort studies of PWUD which facilitate our ethno- epidemiological research and ability to combine clinical and qualitative data. Building on our research infrastructure and experience studying HIV prevention and treatment among PWUD, we propose to examine the following aims: · AIM 1. To examine the impact of the COVID-19 pandemic, including public health measures such as stay-at-home orders and physical distancing, on co-management of HIV and other health conditions among PWUD living with HIV and complex comorbidities. · AIM 2. To identify systems-level barriers and facilitators to HIV treatment during the COVID-19 pandemic, including ART dispensation, particularly among people requiring HIV treatment assistance with complex comorbidities, and identify organizational adaptations made during the COVID-19 pandemic by HIV service organizations with comprehensive care models. 6